MIGI
Mawson Infrastructure Group Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
wize pharma, inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including des. wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as lo2a, a drug developed for the treatment of des, and other ophthalmological illnesses, including cch and sjögren's syndrome (sjögren's). lo2a is currently registered and marketed by its inventor in germany and switzerland for the treatment of des, in hungary for the treatment of des, cch and sjögren's and in the netherlands for the treatment of des and sjögren's. wize's strategy involves engaging local or multinational distributors to handle the distribution of lo2a. wize has finished a phase ii trial of lo2a for patients with cch and is currently conducting a phase iv study for lo2a for des in patients with sjögren's.
Market Cap: 20.8 Million
Primary Exchange: NASDAQ
Website: https://www.wizepharma.com/
Shares Outstanding: 16.6 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.4250524310499688
Sector: Information
Industry: Data Processing, Hosting, and Related Services
Ethical Flags
Longest drawdown: 731 trading days
From: 2021-11-03 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|